|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61K 45/06 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 9/0019 | (2013.01) | ||
| A61K 47/26 | (2006.01) | ||
| C07K 16/2818 | (2013.01) | ||
| A61K 31/357 | (2006.01) | ||
| A61K 31/357 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K2300/00 | (2013.01) | ||
| A61P 35/04 | (2006.01) | ||
| A61P 15/00 | (2018.01) | ||
| A61P 15/14 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/04 | (2018.01) | ||
| A61P 43/00 | (2018.01) |
| (11) | Patento numeris | 3265122 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16710891.9 |
| Europos patento paraiškos padavimo data | 2016-03-03 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-01-10 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2022-05-04 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2016/020734 |
| Data | 2016-03-03 |
| (87) | Numeris | WO 2016/141209 |
| Data | 2016-09-09 |
| (30) | Numeris | Data | Šalis |
| 201562128373 P | 2015-03-04 | US | |
| 201562264068 P | 2015-12-07 | US |
| (72) |
MATSUI, Junji , JP
AKTAN, Gursel , US
KARANTZA, Vassiliki , US
YUAN, RuiRong , US
FUNAHASHI, Yasuhiro , JP
BERRAK, Erhan , US
|
| (73) |
Merck Sharp & Dohme Corp. ,
126 East Lincoln Avenue, Rahway, NJ 07065,
US
Eisai R&D Management Co., Ltd. , 6-10, Koishikawa 4-chome Bunkyo-ku, Tokyo 112-8088, JP |
| (54) | COMBINATION OF PEMBROLIZUMAB AND ERIBULIN FOR TREATING TRIPLE-NEGATIVE BREAST CANCER |
| COMBINATION OF PEMBROLIZUMAB AND ERIBULIN FOR TREATING TRIPLE-NEGATIVE BREAST CANCER |